U.S. Cardiac Troponin Market Size, Share & Industry Analysis, By Type (Troponin T and Troponin I), By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Setting (Laboratory Testing and Point-of-Care (POC) Testing), By End-user (Hospitals & Clinics, Diagnostic Laboratories, and Homecare Settings & Others), and Country Forecast, 2024-2032

The U.S. cardiac troponin market size was worth USD 1.11 billion in 2023 and is projected to grow at a CAGR of 8.5% during the forecast period.

Cardiac troponin proteins are pivotal in both cardiac and skeletal muscle contraction. Troponin I and troponin T are cardiac regulatory proteins that govern the calcium-mediated interaction between actin and myosin. They act as specific markers for heart muscle damage and assist in diagnosing various cardiovascular conditions, including heart disease and acute coronary syndrome.

Changes in troponin levels are critical in diagnosing acute myocardial infarction, distinguishing it from chronic conditions such as heart or renal failure.

The COVID-19 pandemic positively affected the cardiac troponin market by increasing testing within the U.S. population. The strong link between COVID-19 and cardiovascular issues led to heightened demand for troponin testing among COVID-19 patients, contributing to market growth.

LATEST TRENDS

Strong Focus on the Development of Technologically Advanced Products 

In recent years, the U.S. cardiac troponin market players are shifting their focus to develop and launch products for troponin protein that can be used in point-of-care settings. The market players are increasingly involved in the introduction of POC tests to fulfill the growing demand by end-users. Moreover, the introduction of high-sensitivity troponin assays is also identified as an upward trend in the market.

• For instance, Abbott launched the ARCHITECT STAT High Sensitivity Troponin-I blood test, which was approved by the U.S. FDA in September 2019.

DRIVING FACTORS

Rising Prevalence of Cardiovascular Diseases to Drive Demand for Cardiac Troponin Testing

The prevalence of key heart diseases, including coronary heart disease (CHD), stroke, high blood pressure, and others, is rapidly increasing in the country. Cardiac troponin test is often used to determine the severity of damage to the cardiac muscles. Increased levels of this protein in the body are the indicators of a high risk of heart attack or any cardiac-related indication.

The growing demand for this test for diagnosis and management of various cardiovascular diseases is anticipated to propel market growth in the near future.

• According to the CDC data updated in May 2023, around 805,000 people in the U.S. have a heart attack every year.


• Similarly, about 1 in 20 adults aged 20 and older in the country have coronary artery disease, which is the most common type of heart disease.                                       

In the U.S., cardiovascular diseases are the leading cause of death, with coronary heart disease accounting for around 41.2% of deaths attributable to CVD in the country. Hypertension and diabetes are major factors leading to CVD, having around 160 million and 32 million patients, respectively, in 2022.

RESTRAINING FACTORS

Declining Rate of Heart Attack Mortality to Limit Product Adoption

One significant factor impeding the U.S. cardiac troponin market growth is the declining mortality rate associated with heart attacks. According to data published by the American College of Cardiology, the death rate attributed to Coronary Heart Disease (CHD) in the U.S. decreased by 31.8% from 2006 to 2016. Similarly, for cardiovascular diseases, the decline was 18.6%. This continual decrease in mortality rates could negatively affect the adoption of troponin testing products, consequently limiting the market growth in the U.S.

SEGMENTATION

By Type Analysis

Based on type, the market is segmented into troponin T and troponin I.

The troponin I segment dominated the U.S. market in 2022. This type of troponin is deemed a more specific marker for assessing the risk of cardiovascular disease. It is frequently utilized in predicting heart attacks.

On the other hand, the troponin T segment is projected to grow at a comparatively slower rate over the study period. This can be attributed to the supportive regulatory scenario in the country, resulting in increased product approvals in the cardiac troponin market in the U.S.

By Indication Analysis

Based on indication, the market is segmented into congestive heart failure, myocardial infarction, acute coronary syndrome, and others.

In 2022, the acute coronary syndrome segment dominated the U.S. market. Rapidly increasing disease burden due to several factors is majorly driving the segment’s growth. Cardiac troponin is considered the prime diagnostic method for the diagnosis of the disease.

On the other hand, the myocardial infarction segment is anticipated to witness a significant growth over the forecast period. The increasing need for the management of myocardial infarction is expected to boost the segment’s growth.

By Setting Analysis

Based on setting, the market is segmented into laboratory testing and point-of-care (POC) testing.

The laboratory testing segment captured the dominating market share in 2022. Key factors contributing to the dominance of the segment include the fact that troponin tests are easily available in laboratory settings. Additionally, the growing demand for these tests among the patient population also supported the segment growth.

The point-of-care (POC) testing segment is estimated to witness the fastest growth in the near future. Recent new product launches, coupled with the introduction of advanced technologies for cardiac troponin testing, have majorly driven the segment's growth.

By End-user Analysis

Based on end-user, the market is divided into hospitals & clinics, diagnostic laboratories, and homecare settings & others.

In 2022, the hospitals & clinics segment accounted for the largest U.S. cardiac troponin market share. Key factors bolstering the dominance of the segment include a rising number of patient visits to hospitals and clinics for cardiac-related issues. Additionally, increased awareness about cardiovascular diseases among the population is expected to augment segment growth.

Meanwhile, the diagnostic laboratories segment is projected to experience substantial growth throughout the forecast period. The high prevalence of cardiovascular diseases leads to increased demand for troponin testing, thereby positively impacting the segment's growth.

KEY INDUSTRY PLAYERS

The marketspace scenario of the U.S. market is moderately fragmented, featuring a substantial presence of both global and domestic players. No single organization is singularly responsible for the market's future growth.

Key players in the market include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthcare Private Limited, and Beckman Coulter, Inc. These entities are undertaking various strategic initiatives with an aim to expand their product portfolio.

• For instance, in June 2023, Abbott's Alinity I Stat High Sensitivity Troponin-I chemiluminescent microparticle immunoassay received separate 510(k) clearance from the U.S. FDA.

Other operating players in the market include PerkinElmer Inc., bioMérieux SA, LifeSign LLC, among others. These companies are adopting strategies such as collaborations with other players to strengthen their market presence.

LIST OF KEY COMPANIES PROFILED:

• F. Hoffmann-La Roche Ltd. (Switzerland)


• bioMérieux SA (France)


• Abbott (U.S.)


• Siemens Healthineers AG (Germany)


• PerkinElmer Inc. (U.S.)


• Beckman Coulter, Inc. (Danaher) (U.S.)


• LifeSign LLC. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• May 2021: PerkinElmer Inc. completed the acquisition of Immunodiagnostic Systems Holdings PLC to strengthen its presence in the immunodiagnostics segment.


• April 2021: Roche announced five expanded uses for two Elecsys biomarkers, namely N-terminal pro-brain natriuretic peptide and high-sensitive cardiac troponin T (cTnT-hs) test.


• September 2019: The U.S. FDA approved Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test to help diagnose heart attacks faster.

REPORT COVERAGE

The market research report provides a detailed analysis of the market. It focuses on key market segments such as type, indication, setting, and end-user. In addition, it includes detailed insights on market dynamics, new product launches, key industry developments such as mergers, partnerships, & acquisitions, and the impact of COVID-19 on the market. The report also consists of several factors that have contributed to the market growth. The report also provides the competitive landscape of the market at the U.S. level.

Report Scope & Segmentation